Johnson & Johnson Return on Investment 2010-2024 | JNJ
Current and historical return on investment (ROI) values for Johnson & Johnson (JNJ) over the last 10 years.
| Johnson & Johnson ROI - Return on Investment Historical Data |
| Date |
TTM Net Income |
LT Investments & Debt |
Return on Investment |
| 2024-09-30 |
$17.63B |
$101.45B |
17.88% |
| 2024-06-30 |
$19.51B |
$103.17B |
19.99% |
| 2024-03-31 |
$20.06B |
$95.10B |
20.20% |
| 2023-12-31 |
$15.06B |
$94.66B |
14.77% |
| 2023-09-30 |
$12.72B |
$97.28B |
12.20% |
| 2023-06-30 |
$12.68B |
$110.31B |
12.02% |
| 2023-03-31 |
$12.21B |
$105.80B |
11.73% |
| 2022-12-31 |
$19.36B |
$103.69B |
18.70% |
| 2022-09-30 |
$18.11B |
$102.20B |
17.48% |
| 2022-06-30 |
$16.79B |
$104.65B |
16.28% |
| 2022-03-31 |
$17.61B |
$103.56B |
17.27% |
| 2021-12-31 |
$19.18B |
$104.01B |
19.16% |
| 2021-09-30 |
$19.59B |
$100.40B |
19.97% |
| 2021-06-30 |
$20.14B |
$99.89B |
20.71% |
| 2021-03-31 |
$17.42B |
$96.10B |
18.47% |
| 2020-12-31 |
$16.50B |
$95.91B |
17.94% |
| 2020-09-30 |
$19.07B |
$97.15B |
21.31% |
| 2020-06-30 |
$16.31B |
$88.04B |
18.87% |
| 2020-03-31 |
$19.42B |
$86.69B |
22.43% |
| 2019-12-31 |
$17.33B |
$85.97B |
20.02% |
| 2019-09-30 |
$16.23B |
$85.13B |
18.68% |
| 2019-06-30 |
$19.01B |
$88.48B |
21.32% |
| 2019-03-31 |
$16.94B |
$86.62B |
18.80% |
| 2018-12-31 |
$18.00B |
$87.44B |
19.62% |
| 2018-09-30 |
$17.44B |
$94.11B |
18.83% |
| 2018-06-30 |
$17.80B |
$92.29B |
18.90% |
| 2018-03-31 |
$17.58B |
$93.09B |
18.32% |
| 2017-12-31 |
$17.67B |
$90.84B |
18.21% |
| 2017-09-30 |
$19.44B |
$100.65B |
19.93% |
| 2017-06-30 |
$19.93B |
$99.29B |
20.66% |
| 2017-03-31 |
$20.08B |
$97.36B |
20.95% |
| 2016-12-31 |
$19.80B |
$92.86B |
20.90% |
| 2016-09-30 |
$19.24B |
$96.32B |
20.78% |
| 2016-06-30 |
$18.08B |
$97.01B |
20.11% |
| 2016-03-31 |
$18.92B |
$92.88B |
21.76% |
| 2015-12-31 |
$19.20B |
$84.01B |
22.74% |
| 2015-09-30 |
$18.14B |
$85.63B |
21.43% |
| 2015-06-30 |
$20.83B |
$85.22B |
24.32% |
| 2015-03-31 |
$20.71B |
$82.82B |
23.76% |
| 2014-12-31 |
$20.56B |
$84.87B |
23.11% |
| 2014-09-30 |
$20.61B |
$89.74B |
23.00% |
| 2014-06-30 |
$17.47B |
$91.35B |
20.06% |
| 2014-03-31 |
$16.63B |
$89.93B |
19.79% |
| 2013-12-31 |
$15.47B |
$87.38B |
19.07% |
| 2013-09-30 |
$15.82B |
$79.55B |
20.19% |
| 2013-06-30 |
$15.75B |
$79.31B |
20.39% |
| 2013-03-31 |
$12.99B |
$78.22B |
17.22% |
| 2012-12-31 |
$13.78B |
$76.32B |
18.50% |
| 2012-09-30 |
$10.99B |
$75.19B |
15.08% |
| 2012-06-30 |
$11.51B |
$71.96B |
15.82% |
| 2012-03-31 |
$12.90B |
$74.38B |
17.50% |
| 2011-12-31 |
$12.36B |
$70.05B |
17.08% |
| 2011-09-30 |
$14.27B |
$74.56B |
20.01% |
| 2011-06-30 |
$14.38B |
$75.81B |
20.75% |
| 2011-03-31 |
$15.18B |
$69.12B |
23.16% |
| 2010-12-31 |
$16.95B |
$65.74B |
26.69% |
| 2010-09-30 |
$17.32B |
$66.47B |
28.05% |
| 2010-06-30 |
$17.35B |
$60.79B |
29.01% |
| 2010-03-31 |
$17.39B |
$60.97B |
29.88% |
| 2009-12-31 |
$15.76B |
$58.81B |
28.17% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$351.152B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
